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Abstract
Hepatocellular carcinoma (HCC) has dismal diagnosis due to the presence of underly-
ing cirrhosis, late diagnosis, and limited treatment options. Surgery or liver transplan-
tation is restricted to those with small tumours or well-compensated liver diseases. 
Despite advances in early screening and diagnosis of HCC, survival of patients has not 
improved greatly. Furthermore, treatment options for advanced HCC are restricted to 
best supportive care. Currently, sorafenib is the only drug approved for the treatment of 
advanced HCC patients as well as for those not suitable for transarterial chemoemboli-
zation (TACE). Therefore, there is an urgent need to develop new agents for treatment. 
Hepatocarcinogenesis is a complex multistep process that involves deregulation of vari-
ous signalling pathways. Thus, there is no dominant molecular mechanism in HCC and 
understanding of these pathways provides an opportunity for development of potential 
therapeutic agents in an effort to reverse, prevent or delay tumourigenesis. This review 
will summarise the significance of these pathways in HCC and discuss the therapeutic 
benefits or drawbacks of the potential target agents against these pathways especially 
those that have been part of clinical trials.
Keywords: hepatocellular carcinoma, targeted therapy, sorafenib, signalling pathways, 
immunotherapeutics
1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of liver cancer 
and is the second biggest cause of cancer-related deaths world-wide. The incidence of HCC 
is increasing all over the world but the highest rates of HCC are reported in South-East Asia 
with the leading rate of mortality occurring in China [1]. The risk factors for HCC are well 
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defined, such as hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, alcohol 
consumption, and non-alcoholic steatohepatitis (NASH) [2].
The main reasons for the high rate of mortality are lack of diagnostic methods and limited 
treatment options for patients with advanced HCC. Surveillance programmes to identify 
patients with early HCC, such as by ultrasound sound screening and by serum alpha fetopro-
tein (AFP) levels, are not well implemented. Additionally, AFP levels are also dysregulated 
in benign liver diseases [3]. Some of the treatment options for HCC patients include surgical 
resection, liver transplantation (LTx), radiofrequency ablation (RFA), transarterial chemoem-
bolization (TACE) and sorafenib. Surgery has a 5-year survival rate of 70% but unfortunately 
at the time of diagnosis, only 10–30% of patients are suitable for this option. The biggest risk 
post-surgery is that of recurrence. The 5-year recurrence rate in patients with early HCC is 
about 68% after surgery [4]. LTx is suggested to HCC patients with tumours within the Milan 
criteria (a single lesion ≤5 cm, or up to three lesions ≤3 cm each) and is associated with a 5-year 
overall survival (OS) rate of 75%. However, the limitation of LTx is shortage of organ dona-
tion [5]. RFA is another option for patients with early HCC (<3 cm) and its survival benefits 
are comparable to those with surgical resection. However, high costs of RFA and complica-
tions involving peritoneal bleeding hinder its use [6]. TACE is the standard of care for inter-
mediate HCC with preserved liver function, and with no signs of macrovascular invasion or 
extrahepatic spread. It has reported a median survival of 34 months and a survival benefit at 
1, 3, 5 and 7 year as 82%, 47%, 26% and 16%, respectively. However, TACE is a heterogeneous 
operating technique with variation in efficacy depending on the choice of chemotherapeutic 
agents used [7]. For advanced HCC patients, sorafenib is the only drug approved by the 
Trial name and no. Drug Target Ref
SHARP, NCT00105443 Sorafenib versus placebo VEGFR, PDGFR, Raf [8]
Asia Pacific, NCT00492752 Sorafenib versus placebo VEGFR, PDGFR, Raf [15]
STORM, NCT00692770 Sorafenib versus placebo VEGFR, PDGFR, Raf [17]
REACH, NCT01140347 Ramucirumab versus placebo VEGFR-2 [23]
--, NCT00699374 Sunitinib versus sorafenib VEGFR, PDGFR [26]
LIGHT, NCT01009593 Linifanib versus sorafenib VEGFR and PDGFR [28]
RESOURCE, NCT01774344 Regorafenib versus placebo VEGFR1-3, PDGFR-β, and FGFR-1 [30]
EVOLVE-1, NCT01035229 Everolimus versus placebo mTOR [39]
SILVER, NCT00355862 Sirolimus versus placebo mTOR [43]
METIV-HCC, NCT01755767 Tivantinib versus placebo c-MET [47]
JET-HCC, NCT02029157 Tivantinib versus placebo c-MET [47]
CELESTIAL, NCT01908426 Cabozantinib versus placebo c-MET and VEGFR, PDGFR [48]
--: no name assigned; NCT: ClinicalTrials.gov number; VEGFR: vascular endothelial growth factor receptor; PDGFR: 
platelet-derived growth factor receptor; FGFR: fibroblast growth factor receptor; mTOR: mammalian target of rapamycin.
Table 1. Phase III clinical trials of molecular targets in HCC.
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US Food and Drug Administration (FDA) for treatment and although it improves survival 
compared to placebo in clinical trials it suffers from adverse side-effects and high costs [8]. 
Unfortunately, with a majority of patients still diagnosed at late stage and with clinical phase 
III trials failing to improve survival benefits in intermediate and/or advanced HCC, new 
molecular therapeutics are urgently needed to address the dismal prognosis of HCC. One 
approach is to identify molecular targets from the several signalling pathways that are dys-
regulated in HCC. Several phase III trials have been completed to identify potential molecular 
targets in HCC (Table 1).
2. Vascular endothelial growth factor (VEGF) receptor signalling
Angiogenesis is a critical step for tumour growth and metastasis. With HCC being a highly 
vascular tumour, controlling tumour-associated angiogenesis offers a promising approach to 
inhibiting tumour progression.
VEGF is the most well documented growth factor in angiogenesis. It exerts its effect by binding 
to its receptors, VEGF receptor 1 (VEGF-R1), VEGF-R2, and VEGF-R3, present on endothelial 
cells. VEGF secreted by tumour cells bind to its receptors and results in activation of signal 
transduction pathways promoting cell migration, proliferation, and survival of cancer cells 
leading to angiogenesis. VEGF overexpression is possibly induced by the hypoxic tumour envi-
ronment, activation by epidermal growth factor (EGF) receptor (EGFR) and cyloonxygenase-2 
signalling. Increased levels of VEGF, VEGFRs have been reported in HCC cell lines, tissue and 
serum of HCC patients. High levels of VEGF in HCC patients has been associated to poor OS 
and disease-free survival [9], vascular invasion [10] and portal vein emboli [11]. Additionally, 
Guo et al. [12] and colleagues reported poor prognosis for HCC patients with increased serum 
VEGF following TACE. VEGF is also more commonly expressed in HCV-associated HCC than 
in HBV-associated HCC providing clinical implications for different population of HCCs.
Other growth factors stimulating angiogenesis include fibroblast growth factor receptor 
(FGFR), and platelet-derived growth factor receptor (PDGFR). Overexpression of either of 
these growth factors has also been associated to poor survival. There are four types of FGFRs 
(FGFR1, 2, 3, 4) and the PDGFR consist of PDGFRα and PDGFRβ [13, 14].
Sorafenib is currently the only drug approved for treatment of advanced HCC patients who 
cannot undergo TACE treatment. It is an orally active anti-angiogenic multi-kinase inhib-
itor. Several clinical studies have reported promising results. In the randomised phase III 
SHARP trial (ClinicalTrials.gov number NCT00105443), 400 mg of sorafenib twice daily, sig-
nificantly increased the OS of advanced HCC patients (7.9 months versus 10.7 months) and 
the time to progression (TTP) (2.8 months versus 5.5 months) compared to the placebo group 
[8]. Similarly in another phase III Asia Pacific trial (NCT00492752), sorafenib increased the 
OS and TTP from 4.2 months to 6.5 months and from 1.4 months to 2.8 months, respectively 
[15]. The difference in the OS and TTP results in both studies could be due to patient HCC 
aetiology. The Asia Pacific trail had more HBV-associated HCC compared to the SHARP trial 
(73% versus 12%).
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The use of sorafenib as an adjuvant after surgery or TACE remains doubtful. In a small ret-
rospective study with 36 HCC patients, 12 patients received sorafenib post-surgery and the 
remaining 24 patients had surgery only. The group of patients who received sorafenib post-
surgery had a significantly longer OS (37 months versus 30 months) and TTP (29 months versus 
22 months) [16]. However, in the phase III placebo-controlled study (STORM, NCT00692770), 
which recruited 1602 patients from 28 countries, sorafenib as an adjuvant treatment after sur-
gery/local ablation, did not affect time to recurrence or OS [17]. Similar findings were reported 
in the SPACE trial (NCT00855218). In this phase II trial Lencioni et al. [18] tested the efficacy 
of doxorubicin-eluting beads (DEB)-TACE plus sorafenib versus sorafenib in patients with 
intermediate HCC. The authors did not report a significant improvement in TTP following 
addition of sorafenib to DEB-TACE.
Bevacizumab is an anti-VEGF monoclonal antibody that has demonstrated improved effi-
cacy in patients with unresectable HCC. Treatment with bevacizumab at 5–10 mg/kg pro-
duced partial response (PR) in 14% and disease control rates (DCR) in 56% of patients. A 
phase II trial of bevacizumab with capecitabine and oxaliplatin (chemotherapeutic drugs) also 
showed encouraging results with a median progression-free survival (PFS) of 6.8 months, 
and a median OS of 9.8 months. Twenty three patients had stable disease with overall 77.5% 
disease control rate and eight patients produced (PR) [19]. Hsu et al. [20] investigated the 
combination of bevacizumab plus capecitabine in a phase II study yielding median PFS and 
OS of 2.7 and 5.9 months, respectively.
Ramucirumab is another example of monoclonal antibody targeting VEGFR-2. The above 
mentioned bevacizumab targets the proangiogenic factor VEGF while ramucirumab blocks 
the receptor. In a phase II study involving advanced HCC patients, ramucirumab monother-
apy yielded a disease control rate (DCR) of 50%, PFS of 4.0 months and OS of 12 months [21]. 
The promising results from this study lead to a phase III trial (REACH, NCT01140347) of 
ramucirumab monotherapy in advanced HCC patients (post-sorafenib). Although ramuci-
rumab did not improve OS, interestingly in a sub-group of HCC patients with AFP base line 
levels ≥400 ng/mL, ramucirumab significantly enhanced the OS [22].
Sunitinib is an orally administered multi-kinase inhibitor with activity against various 
kinases including VEGFR and PDGFR. It has been approved for treatment of renal cell carci-
noma (RCC), and imatinib-resistant gastrointestinal stromal tumours (GIST). However, it is 
not considered for HCC patients due to its high toxicity. In two phase II studies of sunitinib, 
50 mg daily of sunitinib orally, 4 weeks on and 2 weeks off, both Barone et al. [23] and Faivre 
et al. [24] reported high toxicity. Barone et al. [23] observed treatment-related deaths in 18% 
of patients and with PR in 12% of patients. Median TTP was 2.8 months and median OS 
was 5.8 months. Faivre et al. [24] reported 10% deaths related to treatment and 80% patients 
experienced grade 3/4 adverse effects because of which the study could not proceed to the 
second phase and was terminated [23, 24]. Similarly, a phase III trial (NCT00699374) compar-
ing sunitinib to sorafenib was discontinued. Patients were administered 37.5 mg of sunitinib 
once daily or 400 mg of sorafenib twice a day but a majority of patients experienced adverse 
effects such as thrombocytopenia and neutropenia. Additionally, sunitinib did not show a 
better OS than sorafenib [25].
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Linifanib is a multikinase inhibitor targeting VEGFR and PDGFR. In a phase II trial involv-
ing 44 HCC patients with unresectable or metastatic HCC, linifanib yielded a median OS 
of 9.7 months (compared to 10.4 months in patients with Child-Pugh class A hepatic func-
tion) [26]. In an open-label phase III trial (LIGHT, NCT01009593), Cainap et al. [27] com-
pared linifanib with sorafenib treatment in advanced HCC. Both drugs had similar OS 
with 9.1 months for linifanib and 9.8 months for sorafenib. The median TTP was found to 
be 5.4 months and 4.0 months for linifanib and sorafenib respectively. However, linifanib 
caused more adverse side effects than sorafenib, implying sorafenib could be more safe 
than linifanib.
Regorafenib is a novel diphenylurea multikinase inhibiting VEGFR1-3, PDGFR-β, and FGFR-
1. It has been approved for treatment of metastatic colorectal cancer after failure of oxaliplatin 
and irinotecan-based systemic chemotherapy and has also been approved for treatment of 
metastatic gastrointestinal stroma tumours after failure of imatinib and sunitinib. This year 
regorafenib was approved by the FDA as a second-line treatment for HCC. HCC patients 
not responding to sorafenib now have an option of FDA-approved regorafenib as a second 
line of treatment. This makes regorafenib the first FDA approved drug for treatment of liver 
cancer in almost a decade. In a small phase II study involving 36 advanced HCC patients who 
had progressed following sorafenib, regorafenib at 160 mg once daily in cycles of 3 weeks 
yielded a median TTP of 4.3 months median OS of 13.8 months. The side effects of regorafenib 
appeared similar to that of sorafenib such as fatigue, diarrhoea, hypertension and, hand–foot 
skin reaction [28]. A phase III trial of regorafenib (RESOURCE, NCT01774344) involving 573 
patients from 21 countries evaluated the efficacy and safety of regorafenib in HCC patients and 
observed disease progression after systemic first-line treatment with sorafenib. Regorafenib 
treatment resulted in a survival benefit of 2.8 months compared to placebo (10.6 months ver-
sus 7.8 months). The median PSF for patients taking regorafenib was 3.1 months compared 
to 1.5 months for patients taking placebo. The overall response rate was 11% compared to 4% 
of patients taking placebo [29]. Following these promising results from the RESOURCE trail, 
regorafenib was approved by the FDA in April 2017 for the treatment of HCC patients who 
have previously been treated with sorafenib.
3. RAF/MEK/ERK pathway
The mitogen-activated protein kinase (MAPK) cascade consists of serine/threonine kinases, 
which converts extracellular molecules such as growth factors, hormones, and differentia-
tion factors, into intracellular signals for regulating several cellular processes including pro-
liferation, apoptosis and migration. The four core proteins kinases of this pathway include, 
Ras, Raf, MEK and ERK. The pathway is activated by binding of ligand to receptor tyrosine 
kinases (RTK). In the nucleus, phosphorylation of these four protein kinases regulates gene 
transcription. Around 58% of HCC cases have activated MAPK pathway with Ras, MEK, ERK 
and MAPK up regulated in 33%, 40%, 50% and 50% of HCC patients, respectively [30]. This 
pathway has also been shown to be activated by hepatitis virus infections. Dysregulation of 
this pathway by hepatitis B virus X protein has contributed to loss of function of the tumour 
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suppressor p53 [31]. HCV infection has led to anti-apoptotic effect also following activation 
by Ras/Raf/Mek/Erk signalling [32].
Selumetinib is an oral MEK inhibitor. In a small phase II study (NCT00604721) involving 19 
HCC patients with advanced HCC, selumetinib was given at a dose of 100 mg twice per day 
but the study was terminated at interim analysis because there was no response and the TTP 
was only 8 weeks. However western blot of biopsy samples taken pre and post treatment 
showed phosphorylation of MEK1/2, and ERK1/2, suggesting failure of selumetinib was not 
due to lack of target inhibition [33]. A recent phase I study (NCT01029418) looked into the 
safety, maximum tolerated dose (MTD), and tolerability of selumetinib in combination with 
sorafenib in 27 Asian patients with advanced HCC. The MTD of selumetinib was at 75 mg daily 
with sorafenib at 400 mg twice daily. Common treatment-related adverse events included 
diarrhoea, rash, and hypertension, fatigue, anorexia and hand-foot and mouth disease. Seven 
patients had a PR and stable disease for more than 6 months. The OS was 14.4 months. Due to 
the acceptable adverse events, this combination of selumetinib and sorafenib deserves further 
evaluation [34].
Another MEK inhibitor, refametinib, was evaluated in a phase II study (NCT01204177) in 
combination with sorafenib in 95 patients with unresectable HCC. Patients received twice-
daily refametinib at 50 mg plus twice-daily sorafenib at 200 mg (morning)/400 mg (evening), 
with dose escalation to sorafenib 400 mg twice daily after cycle 2. The TTP was 122 days and 
OS was 290 days. Interestingly, the best responders to the combination treatment were those 
harbouring Ras mutation. A recently completed proof of concept phase II trial (NCT01915602) 
of refametinib in combination with sorafenib in Ras mutant HCC has recently been completed 
with results expected soon. Given that Ras mutations are only observed in 3–5% of HCC 
patients, this study raises questions about feasibility and costs of screening large cohort of 
patients to identify a small sub-group with particular mutations.
4. Mammalian target of rapamycin (mTOR) signalling pathway
This pathway is a critical regulator of numerous physiological processes and also plays a piv-
otal role in cell proliferation and metastasis of transformed human cancers including HCC. It 
is upregulated in around 40% of HCC and has been associated to poor prognosis and early 
recurrence independent of underlying liver aetiology [35]. Two mTOR inhibitors have been 
studied in clinical trials.
Preclinical studies have shown everolimus (taken orally) to dose-dependently inhibit tumour 
growth in patient-derived xenograft models of advanced HCC [36]. In a phase I/II study 
(NCT00516165) in advanced HCC patients, Zhu et al. [37] reported daily dose of 10 mg per 
day to be well tolerated in 28 patients producing a medium PFS and OS of 3.8 months and 
8.4 months respectively. The subsequent phase II study involving 28 patients with prior sys-
temic therapy with daily dose of 10 mg could not be completed as two patients remained 
progression free for 24 weeks. Although everolimus was well tolerated this study had some 
limitations including small sample size and lack of randomised control. The efficacy of 
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 everolimus was next investigated in advanced HCC patients who did not respond to sorafenib. 
In a phase III, randomised, double-blind study (EVOLVE-1, NCT01035229) everolimus did 
not show improvement in OS (7.6 months with everolimus, 7.3 months with placebo). In a 
separate phase II study (NCT01005199), patients with advanced HCC were compared to those 
administered sorafenib alone (800 mg) or with everolimus (5 mg) [38]. The results were not 
encouraging and combination of sorafenib with everolimus did not improve efficacy com-
pared to sorafenib alone with median PFS (6.6 months versus 5.7 months), TTP (7.6 months 
versus 6.3 months), and OS (10 months versus 12 months) were similar in the Sorafenib alone 
group versus sorafenib + everolimus, respectively. However, loss of tuberous sclerosis com-
plex 2 (TSC2) in HCC has been reported to be predictive of response to everolimus in HCC 
patients [39]. Immuohistochemical analysis of HCC samples collected in the EVOLVE-1 clini-
cal trial (NCT01035229) had no detection of TSC2 and longer OS than compared to placebo. A 
larger study is needed to validate the potential of everolimus before it can be used to stratify 
HCC patients for response to everolimus.
Another mTOR inhibitor, temsirolimus (taken intravenously) has not improved survival 
either alone or in combination with either sorafenib [40] or bevacizumab [41]. In a recently 
concluded phase III study (SILVER, NCT00355862), another mTOR inhibitor, sirolimus, did 
not improve recurrence-free survival (RFS) or OS beyond 5 years in Ltx recipients with HCC 
but it did improve RFS and OS within 3–5 years. This may suggest the potential use of siroli-
mus for selection of immunosuppression in LTx recipients with HCC [42].
5. c-MET inhibitors
c-Met is a proto-oncogene that encodes the receptor, MET, for the ligand of hepatocyte growth 
factor (HGF). MET is a tyrosine kinase receptor regulating metastatic progression. Binding of 
MET to HGF activates the RAS-MAPK and PI3K-AKT signalling pathways leading to tumour 
development and metastasis. In HCC, c-MET protein is overexpressed in 70% of HCC and has 
been associated to poor prognosis [43].
Foretinib was the first c-MET inhibitor of broad spectrum, including c-Met and VEGFR, to be 
tested in clinical trials. In a phase I/II study (NCT00920192) involving patients with advanced 
HCC, the median TTP was 4.2 months and the OS was 15.7 months. Its toxicity profile was 
also acceptable with the most adverse events including hypertension and anorexia. Baseline 
plasma levels of Interleukin 6 (IL6) and Interleukin 8 (IL8) were identified as independent 
predictors of OS by multivariate analysis. A larger randomised study is needed to warrant 
the effects of foretinib [44].
Tivantinib is a selective oral inhibitor of c-MET. In a randomised, placebo controlled phase II 
study (NCT00988741), advanced HCC patients were administered 240 mg daily resulting in 
a small improvement in TTP (1.4 months versus 1.6 months) compared to the placebo group. 
Additionally, HCC tumours expressing high levels of c-MET protein, as judged by immuno-
histochemical analysis, demonstrated an improved OS (7.2 months versus 3.8 months) and 
longer TTP (2.7 months versus 1.4 months) compared to placebo. There was no difference 
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in OS and TTP in HCC patients with c-MET protein expression between tivantinib and pla-
cebo. These results suggest the potential of c-met protein expression to select HCC patients 
who may benefit from tivantinib [45]. However, surprisingly, two large randomised dou-
ble-blind placebo-controlled phase III trials i.e. METIV-HCC (NCT01755767) and JET-HCC 
(NCT02029157), have both failed to demonstrate improved OS in advanced HCC patients 
with high c-met protein expression [46].
Cabozantinib is also an oral inhibitor of c-MET, VEGFR and PDGFR. In vitro and in vivo stud-
ies have demonstrated its reduced invasive and migratory properties in HCC. A phase II 
randomised trial is on-going to investigate the efficacy to cabozantinib in solid tumours. A 
phase III, randomised, double-blind, controlled trial is underway to evaluate the efficacy of 
cabozantinib versus placebo as a second-line treatment for advanced HCC who have received 
prior sorafenib (CELESTIAL, NCT01908426) [47].
6. Other potential therapeutic targets in HCC
6.1. Wnt/β-catenin signalling
The Wnt/β-catenin signalling plays a pivotal role in a host of physiological and pathophysi-
ological processes such as embryonic development, cell proliferation, regeneration, angiogen-
esis and cancer [48]. It is also an important player in maintaining liver health, but it is found to 
be dysregulated in HCC with mutation in β-catenin observed in about 40–70% of HCC cases, 
proving to be a potential important target of therapy.
At physiological levels β-catenin is regulated by a destruction complex consisting of adeno-
matous polyposis coli (APC)/Axin/glycogen synthase kinase 3b (GSK3β), and casein kinase 
1 (CK1) which phosphorylates β-catenin at Ser33, Ser37, Thr41, and Ser45 residues located in 
exon 3. The phosphorylated β-catenin is polyubiquitinated by β-transducin repeat containing 
protein (β-TrCP) and degraded by the proteasome. However, wnt signalling is activated upon 
binding of the wnt to one of the frizzled (FZD) family members and to low- density lipopro-
tein receptor-related protein 5 (LRP5) or LRP6, resulting in the inhibition of β-catenin degra-
dation. The accumulated cytoplasmic β-catenin translocates to the nucleus where it forms a 
complex with T-cell factor (TCF)/lymphoid, displacing the transcriptional inhibitor Groucho, 
and the β-catenin-TCF complex enhances transcription of target genes that are implicated in 
cancer development for example, c-Myc and cyclin D1.
Nuclear β-catenin accumulation has been found to be associated to tumour progression and 
poor prognosis. Cytoplasmic β-catenin accumulation has been reported in HCCs larger than 
5 cm in diameter and with reduced disease-free survival. Dysregulation of the wnt/β-catenin 
signalling has also shown to regulate angiogenesis and metastasis [49]. Aberrant activation 
of wnt signalling has also resulted from deregulation of other components of the pathway 
e.g. up regulation of wnt genes (Wnt3, Wnt4 and Wnt5A) and FZD (FZD3, FZD6 and FZD7) 
in about 60–90% of HCCs with more than 5% occurring in peritumours, implying that their 
expression could be an early event in hepatocarcinogenesis [50].
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Disruption of β-catenin and TCF association in the nucleus by two fungal-derived compounds, 
PKF115-584 and CGC049090, has shown dose-dependent cytotoxicity against HCC cells and 
10 times reduced toxicity in normal hepatocytes [51]. The disruption reduced expression of 
wnt/β-catenin target genes (c-Myc, cyclin D1, survivin) and inhibited in vivo tumour growth 
[52]. For reasons yet to be delineated, the presence of EpCAM, hepatic stem cell marker and 
a direct target of the wnt/β-catenin pathway, sensitised HCC cells to these antagonists [53]. 
Together these results suggest that EpCAM expression may facilitate HCC prognosis by effec-
tive stratification of HCC patients responsive to wnt/β-catenin signalling antagonists.
Recently, two FDA-approved drugs have been identified to antagonise wnt/β-catenin path-
way by differing mechanisms. First, pyrvinium was identified in a chemical screen for small 
molecules. It binds to CK1 potentiating its activity and leading to stabilisation of the destruc-
tion complex resulting in degradation of cytoplasmic and nuclear levels of β-catenin [54]. 
Recently, Pimozide, an antipsychotic drug, has been shown to inhibit cell proliferation and 
apoptosis in HCC cell lines by reducing EpCAM and β-catenin [55]. The specific role of these 
inhibitors has yet to be completely elucidated.
Another class of compounds regulate the wnt/β-catenin pathway by inhibiting tankyrases 
(TNK1 and TNK2). TNKs destabilise Axin leading to β-catenin stabilisation. Thus, inhibi-
tion of TNKs prolongs half-life of Axin preventing β-catenin accumulation. These compounds 
include XAV939 and WXL-8 and also reduce tumourigenicity in vivo [56].
Another therapeutic strategy to regulate the wnt/β-catenin signalling is to block the inter-
action between wnt ligands and FZD receptors. This has been achieved with monoclonal 
antibodies or using recombinant soluble fragment of FZD (sFZD). A monoclonal antibody, 
OMP-18R5, developed using the extracellular domain of FZD7, binds to five FZD receptors 
and blocks wnt signalling. It inhibits in vivo tumour growth and acts synergistically with 
chemotherapeutic drugs including taxol, irinotecan and gemcitabine [57]. OMP-18RS, is 
the only potential compound targeting the wnt pathway to make it to clinical phase I tri-
als (NCT01345201) for the treatment of solid tumours and myeloid malignancies, suggesting 
potential use for HCC treatment.
Sorafenib has also been proposed as a potential wnt modulator, decreasing β-catenin and also 
expression of liver-specific wnt targets (GLUL, LGR5, and TBX3) in several HCC cell lines 
accompanied by reduced tumour volume in vivo using HepG2 xenografts in nude mice [58].
Several studies have also evaluated the significance of combination therapy for targeting the 
wnt pathway. A small molecular target, FH535 inhibits proliferation of HCC cell lines by 
inhibiting recruitment of β-catenin coactivators and also suppresses peroxisome proliferator-
activated receptor (PPAR) signalling. Galuppo et al. [59] reported FH535 and sorafenib syn-
ergistically inhibited HCC cell line and liver cancer stem cells by targeting the RAS/RAF/
MAPK and WNT/β-catenin pathways. Western blot demonstrated cleaved increased poly 
(ADP-ribose) polymerase (PARP) and reduced cyclin D1 and c-Myc.
Identification of pharmacological inhibitors of the wnt/βcatenin pathway is still underway. In 
the complex network of wnt ligands, receptors and β-catenin, preclinical studies have yielded 
promising results but wnt inhibitors targeting HCC have not yet reached clinical trials.
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6.2. Immunotherapeutics
Immune checkpoints are emerging as promising targets for treatment of HCC. The immune 
system helps to distinguish body’s own cells from foreign cells. To help it achieve this, 
immune checkpoints which are molecules on certain immune cells, need to be activated or 
inactivated to start an immune response. Cancer cells find ways to use such checkpoints to 
escape immune response.
Programed death-1 (PD-1) is a check-point receptor found on CD8+T-cells and directs it from 
attacking other cells in the body. PD-1 binds to PD ligands (PDL)-1 and PDL-2. Cancer cells 
have high amount of PD-1 and PDL-1 which helps them evade immune response. In HCC, 
CD8+ T-cells that express PD-1 is much higher in both tumour regions and peripheral blood 
compared to healthy controls [60, 61]. Additionally, several correlative studies have associ-
ated PD-1 and PDL-1 in tumours to be significantly associated with HCC recurrence, and 
poor prognosis [62, 63]. Monoclonal antibodies against PD-1 and PD-L1 have been developed 
and are under clinical trials in HCC patients.
Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) is another example of an immune 
check-point, which serves an inhibitory co-receptor that interferes with T cell activation and 
proliferation. CTLA-4 pathway downregulates an immune response by binding to CD80. 
Inhibiting the CTLA-4 pathway leads to T-cell activation and proliferation and may help gen-
erate memory T cells. Monoclonal antibody against CTLA-4 are also under trial in HCC [64].
Pembrolizumab and nivolumab are monoclonal antibodies targeting PD-1. A phase II study 
(KEYNOTE-224, NCT02702414) is currently underway to access the toxicity and activity 
of pembrolizumab in advanced HCC patients who have been treated with sorafenib. The 
primary objective of this study is to determine the objective response rate (ORR) of pembro-
lizumab given as monotherapy. Recently, a case study reported a decrease in tumour size 
and AFP levels in a 75 year old man with metastatic HCC who was treated pembrolizumab 
after failure to respond to sorafenib [65]. Another single-arm phase II trial of pembroli-
zumab is underway (Keytruda, NCT02658019) and is recruiting advanced HCC patients 
with unresectable HCC. The primary end points of this study are PFS, OS, RR, duration of 
response and toxicity.
A phase I/II study is underway (CheckMate040, NCT01658878) to evaluate the safety and 
tolerability of nivolumab. HCC patients who were either not responsive to sorafenib or 
failed sorafenib are also included in the study. Another phase III study (CheckMate-459, 
NCT02576509) is recruiting HCC patients to compare nivolumab with sorafenib as a first line 
treatment for advanced HCC patients.
Durvalumab is a monoclonal antibody targeting PDL-1. A phase II study (NCT02519348) is 
currently recruiting patients with unresectable HCC to evaluate durvalumab and tremelim-
umab either alone or in combination.
Tremelimumab is an inhibitor of CTLA-4. In a small pilot clinical trial including 21 patients 
with metastatic HCV-related HCC, tremelimumab induced a significant decrease in viral load 
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and showed promising partial response rate and disease control rate of 17.6% and 76.4%, 
respectively. The TTP was 6.5 months [66].
6.3. Epigenetic-based therapeutics
Chromatin remodelling is a critical epigenetic mechanism regulating gene expression and 
plays an important role in cell proliferation, differentiation and DNA repair. Epigenetics 
alters gene expression without any changes to the DNA sequence and involves the enzymatic 
covalent modification of histones such as methylation, phosphorylation and acetylation. 
Histone deacetylases (HDACs) remove the acetyl group from histones, making DNA more 
compact resulting in gene silencing. There are a total of 18 HDACs identified in mammals. 
Accumulating evidence suggests the overexpression of HDACs to be correlated advanced 
tumour stage, recurrence after surgery and poor prognosis in several cancers including HCC 
[67, 68]. For these reasons HDAC inhibitors may serve as potential therapeutic targets.
Currently 2 HDAC inhibitors have been approved by the FDA i.e. vorinostat and romidep-
sin, for treatment of cutaneous T cell lymphoma. These inhibitors demonstrate anti-tumour 
activity by means of histone hyperacetylation reducing DNA-histone affinity and allow-
ing access to transcription factors enhancing gene expression. Currently, a phase I clinical 
trial (NCT01075113) is underway to evaluate vorinostat in combination with sorafenib in 
HCC. Romidepsin has not been tested in a clinical setting.
Aberrant up regulation of several HDACs (HDAC1, 2, 3, 4, 5, and 11) and changes in copy 
number of HDAC3 and HDAC5 have been reported in HCC. Treatment with panobinostat 
(HDAC inhibitor) demonstrated strong anti-tumour activity in vitro and in vivo and the effect 
was enhanced in combination with sorafenib [69]. In a recently completed phase I/II trial 
(SHELTER, NCT00943449), combination of resminostat (HDAC inhibitor) with sorafenib 
yielded a progression-free survival-rate of 12.5% for resminostat alone and 62.5% for resmi-
nostat plus sorafenib. Median TTP and OS were 1.8 months and 4.1 months for resminostat 
and 6.5 months and 8.0 months for the combination, respectively [70]. These results support 
further evaluation of HDAC inhibitors in clinical settings in HCC.
7. Conclusion
New therapeutic options are needed for the treatment of HCC despite the availability of 
sorafenib, which has limited survival benefits in advanced HCC patients. Several clinical tri-
als are investigating the efficacy and tolerability of combining sorafenib with other agents. 
Future studies should continue to delineate dysregulated signalling pathways in hepatocar-
cinogenesis to introduce new molecular targets for therapeutic intervention. Simultaneously 
it is critical to identify biomarkers and/or aberrant genotypes that would predict clinical effi-
cacy to these targeted agents. Much work also remains to evaluate the role of targeted therapy 
in adjuvant, neoadjuvant or metastatic settings to determine the most suitable combination of 
treatment. The battle against HCC is far from over and requires a multidisciplinary approach.
Emerging Targeted Therapies for Treatment of Hepatocellular Carcinoma (HCC)
http://dx.doi.org/10.5772/intechopen.71480
183
Author details
Sarwat Fatima1,2*, Nikki Pui-Yue Lee3, Hiu Yee Kwan1,2 and Zhao Xiang Bian1,2
*Address all correspondence to: sarwat@hkbu.edu.hk
1 Lab of Brain and Gut Research, Centre of Clinical Research for Chinese Medicine, School 
of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, 
China
2 Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong 
Baptist University, Kowloon Tong, Hong Kong SAR, China
3 Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
References
[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 
2012. CA: A Cancer Journal for Clinicians. 2015;65:87-108. DOI: 10.3322/caac.21262
[2] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence 
and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. 
International Journal of Cancer. 2015;136:E359-E386. DOI: 10.1002/ijc.29210
[3] Lui HF. Screening for hepatocellular carcinoma. International Journal of Hepatology. 
2011;2011:363151. DOI: 10.4061/2011/363151
[4] Gish RG, Finn RS, Marrero JA. Extending survival with the use of targeted therapy in 
the treatment of hepatocellular carcinoma. Gastroenterology & Hepatology. 2013;9:1-24
[5] Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan crite-
ria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis 
of 15 years of experience. Liver Transplantation: Official Publication of the American 
Association for the Study of Liver Diseases and the International Liver Transplantation 
Society. 2011;17(Suppl 2):S44-S57. DOI: 10.1002/lt.22365
[6] Chen X, Chen Y, Li Q, Ma D, Shen B, Peng C. Radiofrequency ablation versus surgi-
cal resection for intrahepatic hepatocellular carcinoma recurrence: A meta-analysis. The 
Journal of Surgical Research. 2015;195:166-174. DOI: 10.1016/j.jss.2015.01.042
[7] Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study 
of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 
patients. Gastroenterology. 2006;131:461-469. DOI: 10.1053/j.gastro.2006.05.021
[8] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced 
hepatocellular carcinoma. The New England Journal of Medicine. 2008;359:378-390. 
DOI: 10.1056/NEJMoa0708857
[9] Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Serum VEGF as a tumor marker 
in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer 
Research. 2013;33:1013-1021
Hepatocellular Carcinoma - Advances in Diagnosis and Treatment184
[10] Li XM, Tang ZY, Zhou G, Lui YK, Ye SL. Significance of vascular endothelial growth fac-
tor mRNA expression in invasion and metastasis of hepatocellular carcinoma. Journal of 
Experimental & Clinical Cancer Research: CR. 1998;17:13-17
[11] Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, et al. Expression of platelet-derived 
endothelial cell growth factor and vascular endothelial growth factor in hepatocellular 
carcinoma and portal vein tumor thrombus. Journal of Cancer Research and Clinical 
Oncology. 2000;126:57-61
[12] Guo JH, Zhu X, Li XT, Yang RJ. Impact of serum vascular endothelial growth factor on 
prognosis in patients with unresectable hepatocellular carcinoma after transarterial che-
moembolization. Chinese Journal of Cancer Research = Chung-kuo yen cheng yen chiu. 
2012;24:36-43. DOI: 10.1007/s11670-012-0036-8
[13] Wei T, Zhang LN, Lv Y, Ma XY, Zhi L, Liu C, et al. Overexpression of platelet-derived growth 
factor receptor alpha promotes tumor progression and indicates poor prognosis in hepa-
tocellular carcinoma. Oncotarget. 2014;5:10307-10317. DOI: 10.18632/oncotarget.2537
[14] Zheng N, Wei W, Wang Z. Emerging roles of FGF signaling in hepatocellular carcinoma. 
Translational Cancer Research. 2016;5:1-6
[15] Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib 
in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III 
randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2009;10:25-34. 
DOI: 10.1016/s1470-2045(08)70285-7
[16] Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage 
C hepatocellular carcinoma. World Journal of Gastroenterology. 2016;22:4034-4040. 
DOI: 10.3748/wjg.v22.i15.4034
[17] Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib 
for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, ran-
domised, double-blind, placebo-controlled trial. The Lancet Oncology. 2015;16:1344-1354. 
DOI: 10.1016/s1470-2045(15)00198-9
[18] Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo 
plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE 
trial. Journal of Hepatology. 2016;64:1090-1098. DOI: 10.1016/j.jhep.2016.01.012
[19] Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, et al. Phase 2 trial 
of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular 
carcinoma. Cancer. 2011;117:3187-3192. DOI: 10.1002/cncr.25889
[20] Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, et al. Efficacy and tolerability of 
bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocel-
lular carcinoma. British Journal of Cancer. 2010;102(6):981. DOI: 10.1038/sj.bjc.6605580
[21] Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, et al. A phase II and 
biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF 
receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. 
Clinical Cancer Research: An Official Journal of the American Association for Cancer 
Research. 2013;19:6614-6623. DOI: 10.1158/1078-0432.ccr-13-1442
Emerging Targeted Therapies for Treatment of Hepatocellular Carcinoma (HCC)
http://dx.doi.org/10.5772/intechopen.71480
185
[22] Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, et al. 
Ramucirumab as second-line treatment in patients with advanced hepatocellular carci-
noma following first-line therapy with sorafenib: Patient-focused outcome results from 
the randomised phase III REACH study. European Journal of Cancer (Oxford, England: 
1990). 2017;81:17-25. DOI: 10.1016/j.ejca.2017.05.001
[23] Barone C, Basso M, Biolato M, Pompili M, Rufini V, Miele L, et al. A phase II study of 
sunitinib in advanced hepatocellular carcinoma. Digestive and Liver Disease: Official 
Journal of the Italian Society of Gastroenterology and the Italian Association for the 
Study of the Liver. 2013;45:692-698. DOI: 10.1016/j.dld.2013.01.002
[24] Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of 
sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, 
phase II study. The Lancet Oncology. 2009;10:794-800. DOI: 10.1016/s1470-2045(09)70171-8
[25] Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib 
in advanced hepatocellular cancer: Results of a randomized phase III trial. Journal 
of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 
2013;31:4067-4075. DOI: 10.1200/jco.2012.45.8372
[26] Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, et al. Phase 2 trial of linifanib (ABT-
869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 
2013;119:380-387. DOI: 10.1002/cncr.27758
[27] Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib 
in patients with advanced hepatocellular carcinoma: Results of a randomized phase III 
trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical 
Oncology. 2015;33:172-179. DOI: 10.1200/jco.2013.54.3298
[28] Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, et al. Regorafenib as sec-
ond-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, 
open-label, phase II safety study. European Journal of Cancer (Oxford, England: 1990). 
2013;49:3412-3419. DOI: 10.1016/j.ejca.2013.05.028
[29] Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients 
with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A 
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 
2017;389:56-66. DOI: 10.1016/s0140-6736(16)32453-9
[30] Hoffmann K, Shibo L, Xiao Z, Longerich T, Buchler MW, Schemmer P. Correlation of 
gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway 
in patients with hepatocellular carcinoma. Anticancer Research. 2011;31:3883-3890
[31] Wang XW. Microinjection technique used to study functional interaction between p53 
and hepatitis B virus X gene in apoptosis. Molecular Biotechnology. 2001;18:169-177. 
DOI: 10.1385/mb:18:2:169
[32] Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, 
et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in 
Hepatocellular Carcinoma - Advances in Diagnosis and Treatment186
hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis 
C virus infection. Journal of Hepatology. 2008;48:83-90. DOI: 10.1016/j.jhep.2007.08.018
[33] O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, et al. Phase II 
study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with 
advanced hepatocellular carcinoma. Journal of Clinical Oncology: Official Journal of the 
American Society of Clinical Oncology. 2011;29:2350-2356. DOI: 10.1200/jco.2010.33.9432
[34] Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, et al. A phase Ib study of selu-
metinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepato-
cellular carcinoma (HCC). Annals of Oncology: Official Journal of the European Society 
for Medical Oncology. 2017;27:2210-2215. DOI: 10.1093/annonc/mdx060
[35] Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of 
mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-1983. 
DOI: 10.1053/j.gastro.2008.08.008
[36] Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, et al. RAD001 ( everolimus) inhib-
its tumour growth in xenograft models of human hepatocellular carcinoma. Journal of 
Cellular and Molecular Medicine. 2009;13:1371-1380. DOI: 10.1111/j.1582-4934.2008.00364.x
[37] Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, et al. Phase 
1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011;117:5094-
5102. DOI: 10.1002/cncr.26165
[38] Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, et al. Sorafenib with or 
without everolimus in patients with advanced hepatocellular carcinoma (HCC): A ran-
domized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of 
Oncology: Official Journal of the European Society for Medical Oncology. 2016;27:856-861. 
DOI: 10.1093/annonc/mdw054
[39] Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, et al. Loss of tuberous sclero-
sis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to 
mTORC1 inhibitor everolimus. Molecular Cancer Therapeutics. 2015;14:1224-1235. DOI: 
10.1158/1535-7163.mct-14-0768
[40] Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, et al. Temsirolimus 
combined with sorafenib in hepatocellular carcinoma: A phase I dose-finding trial with 
pharmacokinetic and biomarker correlates. Annals of Oncology: Official Journal of 
the European Society for Medical Oncology. 2013;24:1900-1907. DOI: 10.1093/annonc/
mdt109
[41] Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, et al. A phase II trial 
of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. 
Investigational New Drugs. 2015;33:241-246. DOI: 10.1007/s10637-014-0169-3
[42] Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus 
use in liver transplant recipients with hepatocellular carcinoma: A  randomized, 
Emerging Targeted Therapies for Treatment of Hepatocellular Carcinoma (HCC)
http://dx.doi.org/10.5772/intechopen.71480
187
 multicenter, open-label phase 3 trial. Transplantation. 2016;100:116-125. DOI: 10.1097/
tp.0000000000000965
[43] Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y, et al. Expression of the 
c-met protooncogene in human hepatocellular carcinoma. Hepatology (Baltimore, Md). 
1994;20:1231-1236
[44] Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, et al. 
A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients 
with advanced hepatocellular carcinoma. Clinical Cancer Research: An Official Journal 
of the American Association for Cancer Research. 2017;23:2405-2413. DOI: 10.1158/1078-
0432.ccr-16-1789
[45] Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib 
for second-line treatment of advanced hepatocellular carcinoma: A randomised, 
placebo-controlled phase 2 study. The Lancet Oncology. 2013;14:55-63. DOI: 10.1016/
s1470-2045(12)70490-4
[46] Pievsky D, Pyrsopoulos N. Profile of tivantinib and its potential in the treatment of 
hepatocellular carcinoma: The evidence to date. Journal of Hepatocellular Carcinoma. 
2016;3:69-76. DOI: 10.2147/jhc.s106072
[47] Zhang B, Finn RS. Personalized clinical trials in hepatocellular carcinoma based on bio-
marker selection. Liver Cancer. 2016;5:221-232. DOI: 10.1159/000367763
[48] Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. 
Nature Reviews Cancer. 2008;8:387-398. DOI: 10.1038/nrc2389
[49] Qu B, Liu BR, Du YJ, Chen J, Cheng YQ, Xu W, et al. Wnt/beta-catenin signaling pathway 
may regulate the expression of angiogenic growth factors in hepatocellular carcinoma. 
Oncology Letters. 2014;7:1175-1178. DOI: 10.3892/ol.2014.1828
[50] Bengochea A, de Souza MM, Lefrancois L, Le Roux E, Galy O, Chemin I, et al. Common 
dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. 
British Journal of Cancer. 2008;99:143-150. DOI: 10.1038/sj.bjc.6604422
[51] Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, et al. Small-molecule 
antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5:91-102
[52] Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin com-
plex inhibit the growth of HCC cells in vitro and in vivo. International Journal of Cancer. 
2010;126:2426-2436. DOI: 10.1002/ijc.24810
[53] Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker 
EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Research. 
2007;67:10831-10839. DOI: 10.1158/0008-5472.can-07-0908
[54] Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, et al. Small-
molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nature 
Chemical Biology. 2010;6:829-836. DOI: 10.1038/nchembio.453
Hepatocellular Carcinoma - Advances in Diagnosis and Treatment188
[55] Fako V, Yu Z, Henrich CJ, Ransom T, Budhu AS, Wang XW. Inhibition of wnt/beta-
catenin signaling in hepatocellular carcinoma by an antipsychotic drug pimozide. 
International Journal of Biological Sciences. 2016;12:768-775. DOI: 10.7150/ijbs.14718
[56] Ma L, Wang X, Jia T, Wei W, Chua MS, So S. Tankyrase inhibitors attenuate WNT/beta-
catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget. 
2015;6:25390-25401. DOI: 10.18632/oncotarget.4455
[57] Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, et al. Wnt pathway inhibi-
tion via the targeting of Frizzled receptors results in decreased growth and tumorigenic-
ity of human tumors. Proceedings of the National Academy of Sciences of the United 
States of America. 2012;109:11717-11722. DOI: 10.1073/pnas.1120068109
[58] Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, et al. Wnt-pathway 
activation in two molecular classes of hepatocellular carcinoma and experimental mod-
ulation by sorafenib. Clinical Cancer Research: An Official Journal of the American 
Association for Cancer Research. 2012;18:4997-5007. DOI: 10.1158/1078-0432.ccr-11-2322
[59] Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, et al. Synergistic inhibi-
tion of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and 
WNT/beta-catenin pathways. Anticancer Research. 2014;34:1709-1713
[60] Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, et al. PD-1 and PD-L1 upregulation pro-
motes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma 
patients. International Journal of Cancer. 2011;128:887-896. DOI: 10.1002/ijc.25397
[61] Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritu-
moral stroma of hepatocellular carcinoma foster immune privilege and disease progres-
sion through PD-L1. The Journal of Experimental Medicine. 2009;206:1327-1337. DOI: 
10.1084/jem.20082173
[62] Umemoto Y, Okano S, Matsumoto Y, Nakagawara H, Matono R, Yoshiya S, et al. 
Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte 
antigen class I-positive hepatocellular carcinoma after curative hepatectomy. Journal of 
Gastroenterology. 2015;50:65-75. DOI: 10.1007/s00535-014-0933-3
[63] Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 sig-
nificantly associates with tumor aggressiveness and postoperative recurrence in human 
hepatocellular carcinoma. Clinical Cancer Research: An Official Journal of the American 
Association for Cancer Research. 2009;15:971-979. DOI: 10.1158/1078-0432.ccr-08-1608
[64] Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver 
Cancer. 2016;6:1-12. DOI: 10.1159/000449342
[65] Truong P, Rahal A, Kallail KJ. Metastatic hepatocellular carcinoma responsive to pem-
brolizumab. Cureus. 2016;8:e631. DOI: 10.7759/cureus.631
[66] Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. 
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular 
Emerging Targeted Therapies for Treatment of Hepatocellular Carcinoma (HCC)
http://dx.doi.org/10.5772/intechopen.71480
189
carcinoma and chronic hepatitis C. Journal of Hepatology. 2013;59:81-88. DOI: 10.1016/j.
jhep.2013.02.022
[67] Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, et al. Clinical 
significance of histone deacetylase 1 expression in patients with hepatocellular carci-
noma. Oncology. 2007;72:69-74. DOI: 10.1159/000111106
[68] Liu C, Liu L, Shan J, Shen J, Xu Y, Zhang Q, et al. Histone deacetylase 3 participates 
in self-renewal of liver cancer stem cells through histone modification. Cancer Letters. 
2013;339:60-69. DOI: 10.1016/j.canlet.2013.07.022
[69] Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, et al. 
Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the 
HDAC inhibitor panobinostat with sorafenib. Journal of Hepatology. 2012;56:1343-1350. 
DOI: 10.1016/j.jhep.2012.01.009
[70] Bitzer M, Horger M, Giannini EG, Ganten TM, Worns MA, Siveke JT, et al. Resminostat 
plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The 
SHELTER study. Journal of Hepatology. 2016;65:280-288. DOI: 10.1016/j.jhep.2016.02.043
Hepatocellular Carcinoma - Advances in Diagnosis and Treatment190
